Oxycodone Extended-Release (ER) 20 mg

Product Overview

Oxycodone 20 mg Extended-Release (ER) tablets belong to the analgesics category and offer long-lasting pain relief for patients suffering from moderate to severe chronic pain that requires continuous, around-the-clock opioid treatment. Unlike immediate-release formulations, this controlled-release product provides a steady therapeutic dose over 12 hours, helping to maintain consistent pain control and improve patient quality of life.

Oxycodone is a semi-synthetic opioid that primarily activates mu-opioid receptors in the central nervous system, altering pain perception and response. The ER formulation is designed with a matrix system that ensures gradual dissolution and absorption, resulting in prolonged analgesic effect and fewer peak-related side effects.

Key Features and Benefits

• Controlled 12-Hour Release: Delivers oxycodone steadily to maintain prolonged pain relief.

• Effective Management of Chronic Pain: Suitable for patients requiring continuous opioid therapy.

• Consistent Plasma Levels: Minimizes fluctuations in blood concentration, reducing breakthrough pain and side effects.

• Flexible Dosing: Allows healthcare providers to titrate doses for individualized patient needs.

• Oral Administration: Easy-to-swallow tablets encourage adherence.

Indications

Oxycodone 20 mg ER tablets are indicated for:

• Management of moderate to severe chronic pain requiring long-term opioid treatment.

• Patients who need continuous opioid analgesia around the clock, not for acute pain or as-needed use.

Dosage and Administration

• Dosage must be individualized by healthcare providers based on prior opioid exposure, pain severity, and patient response.

• Generally administered every 12 hours to maintain stable analgesia.

• Tablets should be swallowed whole and should not be crushed, chewed, or dissolved to avoid rapid release and potential overdose.

Pharmacology and Mechanism of Action

Oxycodone is a full opioid agonist with strong affinity for mu-opioid receptors and lesser activity at kappa and delta receptors. Upon receptor binding, it inhibits adenylate cyclase activity and decreases cyclic adenosine monophosphate (cAMP) levels, resulting in reduced neurotransmitter release involved in pain signaling. It causes hyperpolarization of nerve cells by opening potassium channels and closing voltage-gated calcium channels, diminishing neuronal excitability and transmission of pain signals.

The extended-release matrix formulation slowly dissolves in the gastrointestinal tract, providing a biphasic absorption pattern: an initial rapid release followed by sustained dissolution, maintaining effective plasma levels for approximately 12 hours.

Safety and Precautions

• Common side effects include constipation, nausea, dizziness, drowsiness, and vomiting.

• Serious risks: respiratory depression, opioid use disorder, and QT prolongation need careful monitoring.

• Contraindicated in patients with severe respiratory depression, acute or severe bronchial asthma, or known hypersensitivity to oxycodone.

• Avoid concomitant use with CNS depressants or other opioids unless under strict medical supervision.

• Not suitable for opioid-naïve patients or use in acute pain requiring immediate relief.

Packaging

• Pink, round, biconvex extended-release tablets containing 20 mg of oxycodone hydrochloride.

• Pack size and regulatory packaging as per market requirements.

About Vonage Pharma

Vonage Pharma manufactures Oxycodone Extended-Release 20 mg tablets following stringent Good Manufacturing Practice (GMP) standards to ensure consistent product quality and safety. Our formulations provide healthcare providers with reliable options for effective chronic pain management, supporting individualized dosing strategies and long-term patient care.